Oxford Cancer Analytics raises £8.9m Series A to scale early lung cancer blood tests
The round was led by We Venture Capital and Cross-Border Impact Ventures to fund the global commercialisation of its liquid biopsy technology.
Oxford Cancer Analytics develops blood tests for early cancer detection using advanced proteomics and machine learning. The firm focuses on minimally invasive diagnostics to improve patient outcomes in oncology.
Oxford Cancer Analytics has raised £8.9m in Series A funding to advance its early cancer detection technology. The investment round was led by We Venture Capital and Cross-Border Impact Ventures, with participation from Eka Ventures, Civilization Ventures, DigitalDx Ventures, Macmillan Cancer Support, Aurelium Ventures, OKG Capital, and angel investors.
The capital will support the company as it prepares to deploy and commercialise its blood tests globally. Alongside the funding, Gemma Sturt of We Venture Capital and Annie Theriault of Cross-Border Impact Ventures have joined the company board, while Dr Heinrich Roder has been appointed as senior vice president of research and development.
From the founder
"Having developed blood-based proteomic tests for lung cancer for over two decades, I appreciate the difficulty of detecting cancers early through liquid biopsy. Convinced that OXcan’s unique approach can address this clinical need, I feel privileged to join the team. Together, our plan is to offer this novel technological approach to large markets worldwide to start a new era of early detection and improve patient outcomes."
Heinrich Roder
Senior Vice President of Research and Development at Oxford Cancer Analytics
Investor perspective
"Macmillan has a proud history of supporting groundbreaking new projects that can transform care for people living with cancer. OXcan’s simple, low cost and accurate blood test has the potential to make it easier to diagnose lung cancer, and to increase the number of people being tested."
Felix Litzkow
Head of Impact Investments, Macmillan Cancer Support
Use of funds
- 01Continue product development
Investors
We Venture Capital
Cross-Border Impact Ventures
Eka Ventures
Civilization Ventures
DigitalDx Ventures
Felix Litzkow
Macmillan Cancer Support
Aurelium Ventures
OKG Capital
Categories
About the company
Oxford Cancer Analytics
Oxford Cancer Analytics develops blood tests for early cancer detection using proteomics and artificial intelligence.